Drugs / TPM XR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01284530 | Jan 2011 → Jun 2012 | epilepsy | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TPM XR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01284530 ↗ |
| Route | Oral | “repeated oral dosing” NCT01284530 ↗ |